Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and Cash
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Viatris (VTRS) PT Lowered to $19 at BMO Capital
March 1, 2022 7:16 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Viatris (NASDAQ: VTRS) to $19.00 (from $23.00) while maintaining an Outperform rating.
The analyst commented, "4Q was in-line, but 2022 guidance was light (though FX is factor, guidance seems conservative). Bigger focus taking stock down was Biocon... More
Viatris (VTRS) PT Lowered to $10 at Cowen
February 28, 2022 12:16 PM ESTCowen analyst Ken Cacciatore lowered the price target on Viatris (NASDAQ: VTRS) to $10.00 (from $15.00) while maintaining a Market Perform rating following weak Q4 results and guidance, and plans to divest some franchises.
The analyst commented, "Following another weak result and 2022 guidance that... More
